Pune, India -- (SBWIRE) -- 05/23/2019 -- The Global Hemoglobinopathy Market is estimated to grow at CAGR above 10 % over the forecast time frame 2019-2026 and reach the market value around USD 12 billion 2026.

Hemoglobinopathies are a variety of congenital blood disorders caused by structural and/or synthesis differences of hemoglobin. Hemoglobinopathy is a genetic single-gene disorder that results in an anemia or other medical abnormalities in one of the hemoglobin molecule's globin chains that cannot carry oxygen through the body. Sickle cell disease, beta thalassemia and alpha thalassemia are the most common hemoglobinopathies.

The growth of the world market for hemoglobinopathy is mainly driven by the increasing prevalence of hemoglobinopathies in developed countries, high-level diseases, a variety of government support initiatives and NGO funding. Advanced diagnostic and therapeutic factors, favorable diagnostic and therapy reward scenarios, economical approaches such as genetic testing and developing rapid point of care diagnostic methods are other factors that drive the global hemoglobinopathy market.

Free Download Sample Report Pages for Better Understanding@ https://www.acumenresearchandconsulting.com/request-sample/1382

Moreover, rising incidence is projected to be a major driving force for market hemoglobin illnesses like sickle cell disease (SCD), thalassemia, Hb C and Hb E. In more than 60% of 229 nations affected by more than 70% of births, hemoglobin illnesses are prevalent, according to the World Health Organization (WHO). There have also been reports of considerable variability in hemoglobin, with a minimum of 5% of the globe inhabitants.

In low-income countries in such areas as Sub-Saharan and Southeast Asia, the prevalence of hemoglobinopathy is high. The ancestral base in these regions is 85% of the affected population of the U.S. and Europe.

Governments work with local institutes to develop sensitisation programs aimed at limiting the effect of the mortality rate associated with hemoglobinopathies. In 2016, for example, in order to raise awareness of this condition and improve individual outcomes, the Sickle Cell Disease Coalition (SCDC) has been founded by the American Society of Hematology (ASH).

Regional Stance

Due to the presence of high unexpected clinical requirements, improved health infrastructure and growing economic levels, the Asia Pacific forecast will show lucrative growth over the period. In addition, it is likely that hemoglobinopathies may further boost growth if low cost diagnostic options are introduced.

Insufficient health infrastructures and low levels of disease diagnostics and treatments are some of the key contributing factors, for example in south-east Asia, the Mediterranean Basin and Africa, for increasing the target population.

In 2018, North America led the overall sales market for hemoglobinopathies. The growth factors are attributed with the increased prevalence of blood disorders, positive government programs and high awareness of hemoglobinopathic genetic testing among health care professionals and patients.

View Detail Information with Complete TOC@ https://www.acumenresearchandconsulting.com/hemoglobinopathy-market

Key Findings

Due to an increase in sickle cell diseases and a strong product pipeline such as LentiGlobin, SCD segments held the largest market share in 2018.

Genetic tests are expected to show lucrative growth over the period forecast for diagnosing sickle cell disorders.

Increasing awareness in conjunction with increasing government programs is expected to increase diagnostic test rates for SCD Genetic diagnostic tests due to rising public awareness and increasing health expenses, and is expected to be more than 8.0% for the forecast period.

Due to the high acceptance and significant success rate of this treatment option and bloody transfusion was the most important treatment segment for hemoglobinopathies.

Key Players & Strategies

With the presence of regional and local players, the world Hemoglobinopathy market is fragmented. The market has been acquired by major companies by key manufacturers. Alnylam Pharmaceuticals; Gamida Cell; Global Blood Therapeutics Inc.; bluebird media Inc.; Emmaus Life Sciences Inc.; Sanofi: Prolong Pharmaciens; and Celgene Corporation are the main business competitors.

Key competitors focus on cooperation and licensing agreements for the exchange of technical knowledge linked to therapeutic haemoglobinopathy. For example, in January 2014, the global cooperation agreement for therapeutic development of hemoglobinopathy was announced by Bioverativ and Sangamo Therapeutics, Inc.

Browse All official Market Research Reports Press Releases@ https://www.acumenresearchandconsulting.com/press-releases

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Hemoglobinopathy
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Hemoglobinopathy Market By Type
1.2.2.1. Global Hemoglobinopathy Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Hemoglobinopathy Market Revenue Share By Type in 2017
1.2.2.3. Thalassemia
1.2.2.4. Beta Thalassemia
1.2.2.5. Alpha Thalassemia
1.2.2.6. Sickle Cell Disease
1.2.2.7. Other Hb Variants Diseases
1.2.3. Hemoglobinopathy Market By Therapy
1.2.3.1. Global Hemoglobinopathy Market Revenue and Growth Rate Comparison By Therapy (2015-2026)
1.2.3.2. Thalassemia
1.2.3.3. Beta Thalassemia
1.2.3.4. Alpha Thalassemia
1.2.3.5. Sickle Cell Disease
1.2.3.6. Other Hb Variants Diseases
1.2.4. Hemoglobinopathy Market By Diagnosis
1.2.4.1. Global Hemoglobinopathy Market Revenue and Growth Rate Comparison By Diagnosis (2015-2026)
1.2.4.2. Thalassemia
1.2.4.3. Beta Thalassemia
1.2.4.4. Alpha Thalassemia
1.2.4.5. Sickle Cell Disease
1.2.4.6. Other Hb variants diseases
1.2.5. Hemoglobinopathy Market by Geography
1.2.5.1. Global Hemoglobinopathy Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Hemoglobinopathy Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Hemoglobinopathy Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Hemoglobinopathy Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Hemoglobinopathy Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Hemoglobinopathy Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter's Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Hemoglobinopathy Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Hemoglobinopathy Major Manufacturers in 2017
3.3. R&D Status and Technology Type of Global Hemoglobinopathy Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Hemoglobinopathy Major Manufacturers in 2017

CHAPTER 4. HEMOGLOBINOPATHY MARKET BY BY TYPE

4.1. Global Hemoglobinopathy Revenue By Type
4.2. Thalassemia
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Beta Thalassemia
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Alpha Thalassemia
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Sickle Cell Disease
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Other Hb Variants Diseases
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. HEMOGLOBINOPATHY MARKET BY THERAPY

5.1. Global Hemoglobinopathy Revenue By Therapy
5.2. Thalassemia
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Beta Thalassemia
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Alpha Thalassemia
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.5. Sickle Cell Disease
5.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.6. Other Hb Variants Diseases
5.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. HEMOGLOBINOPATHY MARKET BY DIAGNOSIS

6.1. Global Hemoglobinopathy Revenue By Diagnosis
6.2. Thalassemia
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Beta Thalassemia
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Alpha Thalassemia
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Sickle Cell Disease
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.6. Other Hb variants diseases
6.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 7. NORTH AMERICA HEMOGLOBINOPATHY MARKET BY COUNTRY

7.1. North America Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Hemoglobinopathy Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Hemoglobinopathy Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 8. EUROPE HEMOGLOBINOPATHY MARKET BY COUNTRY

8.1. Europe Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Hemoglobinopathy Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 9. ASIA-PACIFIC HEMOGLOBINOPATHY MARKET BY COUNTRY

9.1. Asia-Pacific Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Hemoglobinopathy Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 10. LATIN AMERICA HEMOGLOBINOPATHY MARKET BY COUNTRY

10.1. Latin America Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Hemoglobinopathy Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 11. MIDDLE EAST HEMOGLOBINOPATHY MARKET BY COUNTRY

11.1. Middle East Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Hemoglobinopathy Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 12. AFRICA HEMOGLOBINOPATHY MARKET BY COUNTRY

12.1. Africa Hemoglobinopathy Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Hemoglobinopathy Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Therapy, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Diagnosis, 2015 - 2026 ($Million)

CHAPTER 13. COMPANY PROFILE

13.1. Alnylam Pharmaceuticals
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. Gamida Cell
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Global Blood Therapeutics Inc.
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. bluebird media Inc.
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. Emmaus Life Sciences Inc
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Sanofi
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Prolong Pharmaciens
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Celgene Corporation
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Others
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies

CHAPTER 14. RESEARCH APPROACH

14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope

INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/1382

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this Premium Research Report - https://www.acumenresearchandconsulting.com/buy-now/0/1382

Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:
Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to make fact based decisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.